Skip to content

Insulin Resistance in Primary Hyperparathyroidism

Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02711059
Acronym
IRIPH
Enrollment
0
Registered
2016-03-17
Start date
2015-10-31
Completion date
2022-06-30
Last updated
2020-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypercalcemia, Hyperparathyroidism

Keywords

hyperparathyroidism, insulin resistance

Brief summary

The aims of this study is to analyse if insulin resistance in primary hyperparathyroidism (pHPT) is normalised after parathyroid adenomectomy and if glucose tolerance test may be useful as a diagnostic tool by predicting potential improvement of insulin sensitivity after biochemical cure of pHPT.

Detailed description

To be conducted at the Karolinska University Hospital, Stockholm. Patients with fb-glucos \>6.1 and HbA1c without medical treatment will be included after informed consent and randomised to parathyroidectomy (PTX) within three months or not. The groups will be examined 4 ±4 weeks before and 12±2 weeks after PTX, similar for the control group. The number of participants will be estimated by power calculations based on a pilot study including 20 patients. The test protocol includes glucose load with control of glucose and insulin, (0, 30, 60 and 120 min) together with measurement of markers of oxidative stress and inflammation.

Interventions

PROCEDUREparathyroidectomy

surgical treatment of hyperparathyroidism

Sponsors

Karolinska University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* primary hyperparathyroidism and fb-glukos\>6,1 and/or HbA1c \> 39 mmol/mol

Exclusion criteria

* Treatment with insulin, sulfonylurea or metformin

Design outcomes

Primary

MeasureTime frameDescription
glucose tolerance test with estimation of insulin resistance3 monthsHoma IR
quality of life - self estimation protocol3 monthsEORTC QLQ-C30

Secondary

MeasureTime frameDescription
psychological wellbeing3 monthsPOMS
anxiety, depression6 monthsHAD
cognition6 monthsMoCA-Test

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026